Neurosense Therapeutics Ltd. ( (NRSN) ) has provided an announcement.
NeuroSense Therapeutics Ltd. has reported additional positive findings from its completed 18-month Phase 2b PARADIGM study of PrimeC, a treatment for Amyotrophic Lateral Sclerosis (ALS). The study revealed significant improvements in disease progression, overall survival, and complication-free survival for patients initially receiving PrimeC compared to those starting with a placebo. These results could enhance the company’s positioning in the ALS treatment market and have implications for stakeholders involved in ALS research and therapy.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, primarily focusing on the development of treatments for neurodegenerative diseases. The company is known for its drug candidate PrimeC, which is targeted at treating Amyotrophic Lateral Sclerosis (ALS).
Average Trading Volume: 290,742
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $26.71M
Find detailed analytics on NRSN stock on TipRanks’ Stock Analysis page.